Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

165 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to evaluate autologous MSCs as an alternative for antibody induction therapy in renal transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of BM-MSCs in DCD Kidney Transplantation

NCT02561767

Kidney Transplantation Acute Kidney Tubular Necrosis

UNKNOWN PHASE1/PHASE2

Effect of BM-MSCs on Chronic AMR After Kidney Transplantation

NCT02563340

Kidney Transplantation

UNKNOWN PHASE1/PHASE2

Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients

NCT02387151

Rejection Graft Loss

COMPLETED PHASE1

Using MSCs for Chronic Active Antibody Mediated Rejection

NCT07005687

Kidney Transplant Rejection

NOT_YET_RECRUITING NA

Mesenchymal Stromal Cells in Kidney Transplant Recipients

NCT02012153

Kidney Transplant Rejection

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Renal transplantation is the most common and successful type of organ transplantation. Induction therapy with antibody plus the maintenance immunosuppressive agents have greatly improved graft survival in renal transplantation. Since mesenchymal stem cells(MSCs)have been used successfully to treat graft versus host disease and show immune modulation function both in vitro and in vivo and may help in repairing damaged tissue(s), we evaluate autologous MSCs as an alternative for antibody induction therapy. Moreover, we examine if MSCs could improve the recovery of early function in transplanted kidney.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Transplant Rejection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Patients in Group A will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive standard regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF.

Group Type ACTIVE_COMPARATOR

Kidney transplantation with MSCs infusion

Intervention Type PROCEDURE

Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.

B

Patients in Group B will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive 80% less of calcineurin inhibitor than in Group A. Other immunosuppressive agents such as glucocorticoid and MMF remained the same doses as in Group A.

Group Type ACTIVE_COMPARATOR

Kidney transplantation with MSCs infusion

Intervention Type PROCEDURE

Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.

C

Patients in Group C will receive anti-interleukin 2 receptor antibody (Basiliximab)for induction therapy. Patients will receive the same doses of regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF as in Group A.

Group Type ACTIVE_COMPARATOR

kidney transplantation without MSC infusion

Intervention Type PROCEDURE

kidney transplantation with standard immunosuppressive treatment regime

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Kidney transplantation with MSCs infusion

Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.

Intervention Type PROCEDURE

kidney transplantation without MSC infusion

kidney transplantation with standard immunosuppressive treatment regime

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MSCs induction plus a standard or a lower dose of CNI Anti-IL2R induction therapy with standard dose of CNI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must be between the ages of 18 and 60 years and meet the institution's criteria for renal transplantation for end-stage renal failure
* Patient is receiving the first renal transplant
* Patient is receiving a renal transplant only
* Women who are of child bearing potential must have a negative pregnancy test (urine test is acceptable) and agree to use reliable contraception for 1 year following transplant
* Willing to comply with the study visits
* Be able to sign informed consent document.

Note: The subjects do not need to be local residents in order to be eligible for this trial, but must be willing to reside in the area, or within a four hour drive, for the first three months of the protocol so that we can monitor them closely in the early post transplant period.

Exclusion Criteria

* Previously received or is receiving an organ transplant other than a kidney
* Significant liver disease, defined as having continuously elevated AST (SGOT) or ALT (SGPT) levels greater than 3 times the upper value of the normal range within 28 days prior to study entry
* HIV infection.
* Surface antigen positive for HBV.
* Antibody positive for hepatitis C virus
* Recipient or donor is positive for tuberculosis (TB), under treatment for suspected TB, or previously exposed to TB
* Currently receiving an investigational drug or received an investigational drug within 30 days prior to transplant.
* Currently receiving any immunosuppressive agent.
* Clinically active bacterial, fungal, viral or parasitic infection
* Evidence for immunologic memory against donor.
* Recipients need antibody induction treatment before the operation.
* Current cancer or a history of cancer within the 5 years prior to study entry.
* Serious heart and lung diseases.
* Patients who's RPR is positive
* Pregnancy or breastfeeding.
* Have no ability to communicate.
* Any form of substance abuse, psychiatric disorder, or other condition that, in opinion of the investigator, may interfere with the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No